Rhinitis

Researchers are evaluating whether the supplement 5-hydroxytryptophan (5HTP) can improve breathing and reduce anxiety symptoms in children with mild to moderate allergic asthma. This phase 2 study aims to test if 5HTP reduces allergic lung responses, improves lung function measured by Forced Expiratory Volume at one second (FEV1), lowers blood eosinophil counts, and decreases anxiety and depression symptoms. The study is sponsored by Indiana University. Participants will receive either 5HTP or a placebo during two 28-day dosing periods separated by a 3-week washout phase. The 5HTP dose is based on weight: 50mg twice daily for those under 100 lbs, and 100mg twice daily for those over 100 lbs. The study uses a randomized, triple-blind crossover design, meaning participants switch from one treatment to the other during the study. Over about 12 weeks, participants will attend five study visits where lung function tests, blood samples to measure eosinophils, and anxiety/depression questionnaires will be completed. Researchers will monitor changes in lung function, blood markers, and mental health symptoms to evaluate the effects of 5HTP. Safety assessments will ensure participant well-being throughout the study period.

Researchers are evaluating the safety and effectiveness of SHR-1819 injection in treating adults with seasonal allergic rhinitis, a condition causing nasal allergy symptoms during pollen seasons. This phase II study is randomized, double-blind, and placebo-controlled, aiming to understand how the drug affects nasal symptoms and its behavior in the body. Participants are randomly assigned to receive one of two doses of SHR-1819 injection or a placebo. The study includes a treatment period lasting up to 4 weeks, where the impact on nasal symptoms is closely monitored. The trial also tracks safety by recording any adverse events for up to 12 weeks. Throughout the study, participants will complete daily symptom diaries and undergo assessments to measure changes in nasal symptoms using a total nasal symptom score. Researchers will collect data on how the drug is processed in the body and monitor participants' safety. The total participation time may extend beyond the treatment period to capture all necessary outcome and safety information.

This research observes children who took part in the TEMPO clinical trial during their first year of life to understand if their early feeding patterns affect the development of allergies or infections in childhood. The study follows these children up to 7.5 years to gather information on allergic symptoms, infections, and related medical care. It is an observational study without additional treatments or interventions. Participants complete self-administered digital questionnaires every three months using a smartphone, tablet, or computer. These questionnaires collect data on allergies, infections, medication use, medical device use, hospitalizations, and emergency room visits. The study is entirely virtual and decentralized, allowing families to participate remotely. Throughout the study, parents provide information via regular online questionnaires, helping researchers track their child's health over time. The main measurements include parent-reported symptoms, medication or device use, and healthcare visits related to allergies and infections. The study runs until March 2029 and includes children aged 3 to 10 years who completed the original TEMPO study.

This research aims to develop and test a modified minimally invasive surgical technique for sinus floor augmentation in patients with a residual bone height of 3 to 6 millimeters. The goal is to create a reliable implant bed of at least 10 millimeters in height after a healing period of 3 to 5 months. The study also seeks to reduce patient stress compared to traditional methods. Participants will undergo the sinus floor elevation procedure, which is being evaluated to improve outcomes and comfort. This surgical technique is studied on a pilot group of 12 patients, with no placebo or comparative treatments involved. The procedure targets the maxillary sinus area to enhance bone structure for dental implant placement. During the study, participants will be monitored to measure the height of bone augmentation after 4 to 5 months of healing. The research team will assess the surgical results and patient recovery, including any side effects or complications. The total duration includes the surgery followed by the healing and evaluation period to determine the procedure's effectiveness and patient impact.

Researchers are conducting a Phase 1, open-label, randomized crossover study to evaluate how the study drug ibuzatrelvir is absorbed into the bloodstream of healthy adults. The trial compares the amount of ibuzatrelvir in blood after taking different tablet formulations, including the original and new tablets, both with and without food. The study also assesses the safety and tolerability of the medication. Participants will take a single dose of ibuzatrelvir in four different ways across four dosing periods: the original tablet fasted, the new tablet fasted, the new tablet dispersed in water fasted, and the new tablet fed. Each dosing period lasts 2 to 3 days, and participants will stay in the clinical research unit for 9 nights and 10 days to complete all dosing and procedures. The study uses a crossover design where each participant receives all treatment types in varied sequences. During the study, participants will have blood and urine samples collected for safety and to measure drug levels, with up to 40 blood draws for pharmacokinetics. They will also undergo up to 8 ECGs to monitor heart activity. Participants must fast overnight before most doses. After the inpatient stay, a follow-up phone call will occur 28 to 35 days after the last dose. Total participation lasts about 10 to 11 weeks.

Researchers are studying the safety and effectiveness of lebrikizumab in adults with perennial allergic rhinitis, a condition involving year-round nasal allergy symptoms. This phase 3 clinical trial aims to assess how well lebrikizumab works when given alongside standard intranasal corticosteroid therapy. The study is sponsored by Eli Lilly and Company and lasts up to 29.5 months for each participant. Participants will receive lebrikizumab or a matching placebo through subcutaneous injections on different schedules, either every 2 weeks, every 4 weeks, or every 8 weeks, combined with ongoing intranasal corticosteroid use. The trial includes multiple treatment groups with random assignment and double-blind masking to compare the effects of lebrikizumab against placebo while all participants continue their background nasal spray therapy. During the study, participants will have their nasal symptoms evaluated at baseline and at various points, including week 16 and week 56, using symptom scores and quality of life questionnaires. Researchers will monitor changes in nasal symptoms, quality of life, and postnasal drip. Safety and any adverse effects will also be tracked throughout the study duration, with follow-up visits and assessments as scheduled.

Researchers are evaluating the efficacy and safety of Antiwei granules for treating the common cold, specifically the wind-cold syndrome. This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial sponsored by Tasly Pharmaceutical Group Co., Ltd. It aims to assess how well Antiwei granules work and how safe they are in adults aged 18 to 65 with recent onset of common cold symptoms. Participants will be randomly assigned to receive either Antiwei granules or a matching placebo. The treatment involves taking one sachet of granules (6 grams) orally three times a day, for three days. Both groups follow the same dosing schedule, taking nine sachets total. The study compares outcomes between the Antiwei granule group and the placebo group over this short treatment period. Throughout the trial, participants will be closely monitored with assessments focusing on the cure rate after three days of treatment. Researchers will also track symptom recovery time, remission rate, disappearance of individual symptoms, traditional Chinese medicine syndrome efficacy, changes in symptom severity, occurrence of complications, emergency medication use, and overall cure of cough and cold symptoms. The total participation time includes the three-day treatment and monitoring period to evaluate treatment effects and safety.

Seasonal Allergic Rhinitis (SAR) is an inflammatory condition caused by an immune system reaction to allergens such as grass and birch pollen. It affects millions worldwide and causes bothersome nasal symptoms for weeks during allergy seasons. This trial studies acupuncture targeting the sphenopalatine ganglion (SPG), a nerve cluster near the nasal area, to see if it can better relieve SAR symptoms compared to sham acupuncture or medication alone. The study is randomized and aims to provide evidence on acupuncture's safety and effectiveness for SAR. Participants will be randomly assigned to one of three groups: an acupuncture group receiving needles inserted near the SPG to stimulate the nerve, a placebo acupuncture group receiving shallow needle insertion without stimulation, or a rescue medication group receiving no acupuncture but allowed to use medication if needed. Acupuncture sessions involve specific needle placement and stimulation lasting about 30 minutes. The rescue medication group may choose to receive acupuncture after the study period. During the study, participants' allergy symptoms and medication use will be tracked daily for up to eight weeks, with additional follow-up during the next allergy season. Researchers will assess changes in combined symptom and medication scores, quality of life, and global improvements. Participants will complete symptom questionnaires and medication diaries, and their safety will be monitored throughout the trial lasting until the end of 2026.

This research aims to understand how co-existing health conditions, medical history, and allergy tests affect the results of allergen provocation tests in children. The study includes children from birth up to 18 years old who are being investigated for allergies to foods or antibiotics. It is a prospective observational study conducted at the Hans Christian Andersen Children's Hospital. Participants undergo oral provocation tests where small, increasing amounts of allergens are given to assess allergic reactions. The allergens studied include antibiotics and a variety of common food allergens such as milk, egg, peanut, hazelnut, sesame, wheat, various nuts, soy, fish, shellfish, and poppy seed. Each child is assigned to a group based on the specific allergen they are being tested for. During the study, data on demographics, co-existing conditions, symptoms, skin prick tests, specific IgE levels, and details from the provocation tests are collected and entered into a database. Researchers will assess the relationship between allergy test results and provocation outcomes over a five-year period. Children will be monitored through these evaluations to better understand allergy responses and test effectiveness.

Researchers are investigating early warning signs and biomarkers for dementia with Lewy bodies (DLB), a common cause of dementia linked to the buildup of misfolded alpha-synuclein protein in the brain. The study focuses on people with idiopathic olfactory dysfunction—loss or reduction of smell without known cause—to better understand symptom progression and improve early diagnosis, potentially aiding future treatments. Participants include people with and without olfactory dysfunction. The study uses Real-Time Quaking-Induced Conversion (RT-QuIC), a laboratory technique that detects misfolded alpha-synuclein, to assess samples from participants. It involves an exploratory cross-sectional case-control design and a long-term follow-up using Danish health registries to track diagnoses of Parkinson's disease or dementia. During the study, participants undergo smell tests, motor function exams, cognitive assessments, and evaluations of other symptoms related to Parkinson's disease and DLB at regular intervals over 24 months and longer. Researchers monitor the presence of misfolded alpha-synuclein and track diagnoses over up to 8 years. This observational study helps identify early signs and disease progression markers while participants continue their usual care.